QPS, a contract research organization (CRO), continues to expand its global footprint with new clinics in the Netherlands and India and a new bioanalytical facility in China.
QPS Netherlands recently celebrated the grand opening of a second clinic, which is ideally positioned on the grounds of the Medical Center Leeuwarden (MCL). While initial studies will focus on neurodegenerative diseases like Alzheimer’s disease and Parkinson’s disease, the clinic will ultimately be open to studies in a wide variety of disease states. According to Izaak den Daas, PhD, Director of Patient Studies at QPS Netherlands, “From 2017 onwards, discussion between QPS and medical staff and management of MCL resulted in the mutual agreement of the establishment of a dedicated clinical pharmacology patient unit on the premises of MCL in close vicinity of the policlinic stations of the medical specialists.”
Consisting of adaptable function rooms and eight comfortable bedrooms for overnight stays, the facility was specifically designed to address the safety and security needs of elderly patients with Alzheimer’s and Parkinson’s disease. The first patient study will start on September 15, 2019.
In addition, QPS India opened a new early-phase clinical facility in Hyderabad, India, with a 138-bed capacity spread over four clinical units. The facility is ready for Phase I healthy volunteers as well as Phase II/III patient populations. It also includes a dedicated area for women and is easily accessible, ensuring the health and safety of all volunteers.
QPS India is located in a prime area, which makes it accessible to many pharmaceutical companies performing clinical research. One of the most experienced clinical and bioanalytical service providers in India, QPS India delivers comprehensive CRO services across a broad range of therapeutic areas.
QPS India has successfully cleared over 22 regulatory inspections from the U.S. Food and Drug Administration (FDA), Medicines and Healthcare Products Regulatory Agency (MHRA), European Medicines Agency (EMA), World Health Organization (WHO), and Drug Controller General of India (DCGI). In addition, QPS India is a proud partner to several prominent generic pharmaceutical companies and has contributed to first-to-file and 505(b)(2) projects.
“QPS India is well known for quality, compliance, and commitment with a good regulatory track,” says Daniel Rapaka, Deputy General Manager of Business Development at QPS India. “It’s a one-stop solution for all generic bioavailability and bioequivalence (BA/BE) studies and clinical trials.”
Finally, QPS China celebrated the grand opening of a new bioanalytical facility in Suzhou, China, in February 2018. This facility provides critical expertise and bed capacity, helping QPS meet the rapidly expanding need for liquid chromatography-mass spectrometry (LC-MS) and mass spectrometry (MS) laboratories for drug development in China. According to Yongdong Zhu, PhD, Vice President and Head of Bioanalytical Services at QPS Suzhou, “It is a well-equipped, fully GLP-compliant bioanalytical facility.”
With 13 scientists and supporting staff and four cutting-edge LC-MS/MS systems, QPS Suzhou offers a comprehensive array of services. These include method development and validation as well as analysis of drugs and drug metabolites.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Making the Grade: Registries as Sources of Regulatory-Grade Real-World Evidence (RWE)
February 13th 2025Dr. Peter Wahl, MLA, MS, ScD, VP and Global Head of Scientific Affairs at CorEvitas, part of the PPD™ clinical research business of Thermo Fisher Scientific, discusses the critical role of protocol-driven registries in generating regulatory grade RWE to serve multiple and evolving evidence needs across the drug development life cycle. He covers key considerations for selecting the right type of registry, the advantages over EMR datasets, and how registry data contextualizes safety and effectiveness to fulfill FDA and EMA post-marketing requirements.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.